MedTrace Logo

Observational Registry Study: FIREHAWK DES for Treating Coronary Artery Disease (CAD)

NCT01412164 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 730

Last updated 2019-08-26

Study results available
· View outcomes & findings →

Summary

The study aims to further assess the safety, efficacy and the performance of its delivery system of FIREHAWK rapamycin-eluting stent up to five years.

Conditions

Interventions

DEVICE

FIREHAWK biodegradable polymer rapamycin-eluting stent

DES PCI for CAD

Sponsors & Collaborators

  • Shanghai MicroPort Medical (Group) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Runlin Gao, M.D., Prof. · Fu Wai Hospital, Beijing, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2013-02-28
Completion
2017-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01412164 on ClinicalTrials.gov